SRN-901

SRN-901 protects against frailty in mice (70% attenuation, p < 0.001).

“SRN-901 protected mice against increased frailty during aging, with baseline-normalized scores rising to 1.17 in treated mice and 1.57 in controls, corresponding to a 70% attenuation of frailty progression”

Animalsfed a Western dietbetween pre-treatment (D-14) and post-treatment (D128)

SRN-901, a Novel Longevity Drug, Extends Lifespan and Healthspan by Targeting Multiple Aging Pathways

Drug design, development and therapy·15 Apr 2026

SRN-901 extends median remaining lifespan in mice (+33% median remaining lifespan).

“SRN-901-treated mice showed a significant increase of 33% in median remaining lifespan compared to placebo-treated mice.”

Animalsfed a Western diet

SRN-901, a Novel Longevity Drug, Extends Lifespan and Healthspan by Targeting Multiple Aging Pathways

Drug design, development and therapy·15 Apr 2026

SRN-901 lowers the risk of mortality in mice (HR 0.54, 46% reduction).

“Cox proportional hazards analysis revealed a hazard ratio of 0.54, indicating that SRN-901 treatment was associated with a 46% reduction in the hazard of death.”

Animalsfed a Western diet

SRN-901, a Novel Longevity Drug, Extends Lifespan and Healthspan by Targeting Multiple Aging Pathways

Drug design, development and therapy·15 Apr 2026